Replies to post #4149 on Cytodyn Inc (CYDY)

[Amatuer17]

"Management only reports on first and last patient being injected."

That is not true - for long running large trials companies give enrollment updates. I hv few examples like CT_x, RD_L and few BP.

[Amatuer17]

It is not just dilution but the delay that will be problematic in long run.

Also assume that CYDY will be acquired at 6 B

150 million shares mean - SH get $40 per share

200 milion shares --> $30 per share

250million --> $24 per share

Thus as time passes and company raises more money at lower prices - the SH returns start going down faster.

We already reaching 200 million no - wait for 18 more months - we could reach 300 million

So it starts becoming much less attractive